Pulse Biosciences, Inc.
PLSE
$25.57
$1.204.90%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.75% | -23.64% | 47.53% | 82.10% | 99.56% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.35% | -8.61% | 49.78% | 72.91% | 69.99% |
| Operating Income | -6.13% | 9.91% | -49.15% | -72.91% | -69.99% |
| Income Before Tax | -10.63% | 10.07% | -52.88% | -68.39% | -65.68% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.63% | 10.07% | -52.88% | -68.39% | -65.68% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.63% | 10.07% | -52.88% | -68.39% | -65.68% |
| EBIT | -6.13% | 9.91% | -49.15% | -72.91% | -69.99% |
| EBITDA | -6.38% | 9.91% | -50.52% | -75.03% | -72.17% |
| EPS Basic | -9.23% | 17.67% | -38.58% | -43.09% | -40.96% |
| Normalized Basic EPS | -9.21% | 17.67% | -38.52% | -43.17% | -41.03% |
| EPS Diluted | -9.23% | 17.67% | -38.58% | -43.09% | -40.96% |
| Normalized Diluted EPS | -9.21% | 17.67% | -38.52% | -43.17% | -41.03% |
| Average Basic Shares Outstanding | 1.29% | 9.24% | 10.35% | 17.66% | 17.51% |
| Average Diluted Shares Outstanding | 1.29% | 9.24% | 10.35% | 17.66% | 17.51% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |